Sep 18, 2018 - Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Sep 17, 2018 - ‘The New Buffettology’: Finding Durable Competitive Advantages, Stocks: XTER:PAH3,MCD,YUM,BMY,L,CPB,IPG,ROL,SERV,AXP,WMT, Warren Buffett, release date:Sep 17, 2018
Sep 16, 2018 - Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira, Stocks: BMY, release date:Sep 16, 2018
Sep 15, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Sep 15, 2018 - FibroGen's pamrevlumab fast tracked for IPF.Dr. Reddy’s generic launch.Bristol-Myers Squibb succeeds in mid-stage trials.
Sep 14, 2018 - Merck's application for first-line pembrolizumab in a wider patient population has now been accepted.If approved, it could change the dimension of the market for non-small cell lung cancer.What does t
Sep 14, 2018 - Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Sep 14, 2018 - Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.
Sep 13, 2018 - Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 16th Annual Global Healthcare Conference September 13, 2018, 11:10 am ET Executives Giovanni Caforio - Chairman, Chief Executive Officer Analysts
Sep 12, 2018 - With a PDUFA in lung cancer coming up, Pfizer has a seemingly tall uphill climb to face its competition.There remain possible scenarios where Pfizer's drug could gain and hold relevance in the first-l